How Are mRNA Therapeutics Transforming CDMO Manufacturing Requirements?
mRNA therapeutics, including COVID-19 vaccines and emerging therapies for cancer and genetic disorders, have moved from a niche platform to a major pharmaceutical modality in just a few years. This rapid maturation is transforming the requirements placed on CDMOs, driving investment in new manufacturing technologies and processes. The shift is a major driver of growth in the Nucleic Acid...
0 Comments 0 Shares 24 Views 0 Reviews